[Federal Register Volume 75, Number 103 (Friday, May 28, 2010)]
[Notices]
[Page 30003]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-12867]



[[Page 30003]]

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Federal Advisory Committee; Meeting of the Uniform Formulary 
Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) 
the Department of Defense announces that the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel) will 
meet on June 24, 2010, in Washington, DC. The meeting is open to the 
public from 9 a.m. to 12 p.m., but seating is limited. A closed 
Administrative Work Meeting will be held from 8 a.m. to 9 a.m.

DATES: The open meeting will be held on June 24, 2010, from 9 a.m.-12 
p.m. Prior to the open meeting the Panel will conduct an Administrative 
Work Meeting from 8 a.m. to 9 a.m. that is closed to the public.

ADDRESSES: The meeting will be held at the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen, 
Designated Federal Officer, Uniform Formulary Beneficiary Advisory 
Panel, 2450 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234-6102, 
Telephone: (210) 295-1271, Fax: (210) 295-2789, E-mail: 
<a href="/cdn-cgi/l/email-protection#6f2d0e1f1d0a1e1a0a1c1b1c2f1b020e41001c0b41020603"><span class="__cf_email__" data-cfemail="0a486b7a786f7b7f6f797e794a7e676b2465796e24676366">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

Purpose of Meeting

    The Panel will review and comment on recommendations made to the 
Director, TRICARE Management Activity, by the Pharmacy and Therapeutics 
Committee regarding the Uniform Formulary.

Meeting Agenda

    Sign-In; Welcome and Opening Remarks; Public Citizen Comments; 
Scheduled Therapeutic Class Reviews--Alpha Blockers for Benign 
Prostatic Hyperplasia, Antilipidemics I, Designated Newly Approved 
Drugs and Drugs recommended for non-formulary placement due to non-
compliance with Fiscal Year 2008 National Defense Authorization Act, 
Section 703; Panel Discussions and Vote; and comments following each 
therapeutic class review.

Meeting Accessibility

    Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through 
102-3.165, and the availability of space this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing in. All persons must sign in legibly.

Administrative Work Meeting

    Prior to the public meeting the Panel will conduct an 
Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss 
administrative matters of the Panel. The Administrative Work Meeting 
will be held at the Naval Heritage Center (see ADDRESSES). Pursuant to 
41 CFR 102-3.160, the Administrative Work Meeting will be closed to the 
public.

Written Statements

    Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (see FOR FURTHER INFORMATION 
CONTACT). The Designated Federal Officer's contact information can be 
obtained from the General Services Administration's Federal Advisory 
Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The Designated Federal Officer will review 
all submitted written statements and provide copies to all the 
committee members.

Public Comments

    In addition to written statements, the Panel will set aside 1 hour 
for individuals or interested groups to address the Panel. To ensure 
consideration of their comments, individuals and interested groups 
should submit written statements as outlined in this notice; but if 
they still want to address the Panel, then they will be afforded the 
opportunity to register to address the Panel. The Panel's Designated 
Federal Officer will have a ``Sign-Up Roster'' available at the Panel 
meeting, for registration on a first-come, first-serve basis. Those 
wishing to address the Panel will be given no more than 5 minutes to 
present their comments, and at the end of the 1-hour time period no 
further public comments will be accepted. Anyone who signs up to 
address the Panel, but is unable to do so due to the time limitation, 
may submit their comments in writing; however, they must understand 
that their written comments may not be reviewed prior to the Panel's 
deliberation. Accordingly, the Panel recommends that individuals and 
interested groups consider submitting written statements instead of 
addressing the Panel.

    Dated: May 25, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-12867 Filed 5-27-10; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>